Medexus Pharmaceuticals Insider Trading

Medexus Pharmaceuticals is a Canadian pharmaceutical company operating in Canada and the United States. The company focuses on therapeutic areas including allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary prescription products include IXINITY, an intravenous recombinant factor IX treatment for patients with hemophilia B; Rasuvo and Metoject, methotrexate formulations used to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection used in allogeneic hematopoietic stem cell transplantation and the treatment of acute myeloid leukemia and myelodysplastic syndrome. Additional prescription products include Cuvposa, a glycopyrrolate oral solution; a naproxen suspension; Otixal, a ciprofloxacin and fluocinolone acetonide product; and a triamcinolone hexacetonide injectable suspension. The company also markets several over-the-counter products, including Nyda, a topical head lice treatment; Relaxa, an osmotic laxative for occasional constipation; Oralvisc, for osteoarthritis knee pain and joint function; and Calcia calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and adopted its current name in December 2018.